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INTRODUCTION
Prostate cancer is the m ost frequently diagnosed m alignancy and the second leading cause of death am ong men with cancer in the US A. When comparing races, the incidence and mortality rates of prostate cancer in Af rican-Americans is higher than in Caucasians and Asians. Cytochrome P450 (CYP) 1B1 converts estrogens to the 4-hydroxy-catechol-estrogens. Studies show this catechol-estrogen to be m utagenic and may lead to prostate cancer. Polym orphisms of CYP1B1 have been associated with various t ypes of cancers and we have shown that CYP1B1 polymorphisms have higher risks for prostate cancer (Abstract; J. Urol. 171(Suppl. 4):111, 2004) . However, such studies are lacking in race -related prostate cancer. There are at least 4 polymorphisms that have been identified on the CYP1 B1 gene that results in a structural change in the enzyme and are at the following locations: codons 48 (C to G), 119 (G to T), 432 (C to G), and 453 (A to G). The m ain goal of this project is to investigate whether polym orphisms of the CYP1B1 gene can be a risk factor for race-re lated prostate cancer. To determ ine this, two specific aims are tested. In sp ecific aim #1, the hypothesis that CYP1B1 gene is hyper-activated during m alignant transform ation of race-rela ted prostate cells is tested. In the 2 nd aim , the hypothesis that single nucleotide polym orphisms (SNPs) of the CYP1B1 gene have higher risk for race-related prostate cancer and correlate with hyper-activated CYP1B1 gene is tested. Data generated f rom these experim ents will determ ine whether CYP1B1 gene expression dif fers between Caucasian and Af rican-American prostate cancer samples. Also, these experiments will determine whether CYP1B1 SNPs are involved in race-related prostate cancer. This knowledge will help to understand the genetic basis for raci al differences as well as identify the subjects who are at higher risk for prostate cancer.
BODY

Samples:
Unless specified, all specim ens reported are from our previously funded projects that are pre-existing, archival specim ens from African-Americans and Caucasians. cDNA arrays and cell lines are from commercial sources. Experimental results are based on these samples. Task #1. To determine if the CYP1B1 gene is differentially expressed betw een races (African-Americans and Whites) and in different stages and grades of prostate cancer.
CYP1B1 in prostate cell lines from Whites.
Cell lines were utilized to see if there are dif ferences in CYP1B1 expression between cancerous versus normal cells. Prostate cell lines of Caucasian origin were utilized and obtained from ATCC (Manassas, VA). Cancerous cells (DU 145 and PC-3) were cultured in RPMI 1640 (UCSF Cell Culture Facility; San Francisco, CA) with 10% fetal bovine serum (Atlanta Biologicals; Atlanta, GA). Norm al cells (RW PE-1) was cultured in Keratinocyte-SFM +L-Glutamine, +EGF and BPE (GIBCO/Invitrogen; Ca rlsbad, CA). From the prostate cell lines, total RNA was extracted using the Qiagen RNeas y kit according to m anufacturer's instructions. Quantity and quality of RNA was m easured at 260 and 280 nm with the use of a spectrophotometer. RNA was reverse-transcri bed to cDNA using the Prom ega Reverse Transcription System (Madison, WI). To measure CYP1B1 expression in cell lines, cDNA were amplified by PCR and electrophoretically separa ted on 2% agarose gels using 200 volts at ambient temperature. The products were then visualized by ethidium bromide staining under UV light and im age taken on an Alpha Im ager Ge l Docum entation System (Alpha Innotech, San Leandro, CA). Quantitative real-tim e PCR wa s perform ed using the ABI Prism 7500 Fast Thermal Cycler (Applied Biosystem s Inc.; Fo ster City, CA). cDNA was am plified using TaqMan Fast Universal PCR Mast er Mix, RNAse-free water and prim ers specific to either the CYP1B1 gene or glyceraldehyde-3-phospate de hydrogenase (GAPDH), as internal control. Primers were obtained from Applied Biosys tems (Foster City, CA. Catalog Num bers: Hs00164383_m1, and Hs99999905_m 1). Sam ples were rep licated four tim es. Results were tabulated using 7500 Fast System SDS Software version 1.3.1. Figure 1 shows the gel electrophoresis pr oducts of CYP1B1 and GAPDH. CYP1B1 is observed to be expressed in both norm al (RWPE-1) and cancerous (DU145 and PC-3) prostate cell lines f rom Caucasians. Quantitation of CYP1B1 by the real-tim e PCR in these cell lines is shown in Figure 2 . A dram atic 14.5-fold increase of CYP1B1 expression in the PC-3 cancer cell line, and a 17.7-fold increase in the DU145 cancer cell line were observed, as com pared to the normal cell line RWPE-1.
CYP1B1 RNA in prostate tissues.
Since we find an increase of CYP1B1 in pr ostate cell lines, we next evaluated CYP1B1 expression in hum an prostate tissue. W e pe rformed PCR am plification and real-tim e PCR analyses on cDNA acquired from 95 different prostate tissues using TissueScan Prostate Tissue qPCR Arrays (OriGene Technologies; Rockville, MD). These arrays consisted of 11 sam ples from individuals with hyperplasia of the pros tate, 20 sam ples from prostate lesions, and 49 samples f rom prostate tum ors. Lesional cells ar e those that are neither cancerous, nor are they described as "within norm al limits". Information about race/ethnicity was provided for 58 of the patients, of which 3 were Asian, 5 were Af rican Am erican, and 50 were Caucasian. Total Gleason scores ranged from 4 to 9, and cover disease stages I through IV.
Results of PCR am plification run on gels is shown in Figure 3 . CYP1B1 expression was confirmed in W hite BPH, W hite cancer and Black cancer. Since expression were observed, quantitative real-tim e RT-PCR analysis was perf ormed on these sam ples. Figure 4 shows the relative levels of CYP1B1 expression in BPH, le sion, and tum or. Transcripts were detectible in all samples and we observed elevated levels of CYP1B1 in lesion (1.80-fold) and tum or tissues (2.40-fold), as com pared to BPH. W hile insufficient sample size prevented a thorough analysis by race, the sam e pattern of expression was al so observed am ong W hite patients, with lesion having a 1.51-fold increase and tum or having a 3.29-fold increase compared to BPH ( Figure 5 ). Interestingly, we observed a slightly higher (1.36-fold) expression of CYP1B1 in tum or tissues from White patients as compared to African Americans ( Figure 6 ). We found no clear correlation between the expression levels and Gleason scores.
CYP1B1 protein in prostate tissues.
As dem onstrated above, we find CYP1B1 to be expressed in both cell lines and hum an prostate tissues, with RNA levels higher in pros tate tumors compared to BPH tissue or norm al cell lines. W e then investigated CYP1B1 protei n in prostate tissue. Prostate cancer tissue samples were obtained from 15 Caucasian and 15 Af rican Am erican m ales living in the San Francisco Bay Area whom had undergone radical prostatectomy with a pathologically confirmed diagnosis of prostate carcinoma at the Veterans Affairs Medical Center (VAMC), San Francisco, Department of Urology. Specim ens were also obtained from 15 Caucasian and 15 African American m en living in the bay area who ha d pathologically confirm ed benign prostatic hypertrophy (BPH). Relevant clinico-pathologi c data (age, Gleason grade, and tum or-node-metastasis stage) were collected from the patie nt files. The average age for Caucasians with prostate cancer, African Am ericans with prosta te cancer, Caucasians with BPH and African Americans with BPH were 69.9, 67.5, 72.8 and 66.1 years, respectively. All tissues were formalin-fixed and em bedded in paraffin. All specim ens were archived, de-identified, preexisting specimens. Paraffin embedded tissue samples were cut into 5 micron sections and placed onto silanized slides (Dako, Carpinteria, CA). The slides were then incubated at 60ºC overnight. To deparaffinize, slides were treated with xylene three times for 5 minutes each, then 100% ethanol for 10 minutes, 95% ethanol for 10 minutes, 70% ethanol for 5 minutes, and washed in deionized water for one minute. To unmask antigens, slides were then placed in citrate buffer (LabVision; Fremont, CA) and heated in a 900W microwave on high for 7 m inutes. After allowing to cool, endogenous peroxidase activity was quenched by so aking slides in 3% hydrogen peroxide for 8 minutes (Sigm a-Aldrich; St. Louis, MO). Bl ocking serum from Im munoCruz Staining System (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was used m inimize non-specific binding. CYP1B1 polyclonal rabbit antibody (Abcam Inc., Cambridge, MA) was diluted 1:500 in serum block and slides were incubated overnight at 4ºC. Unbound prim ary antibody was rem oved by washing with phosphate-buffered saline (PBS) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) twice. Biotinylated secondary antibody from th e staining kit was added and incubated for 30 minutes. Slides were then washed twice in PB S and incubated for 30 minutes with horse radishStreptavidin reagent. Diam inobenzidine Plus Substrate (UltraVision Plus System ; Labvision; Fremont, CA) was added as a chrom ogen until st aining becam e visible. Finally, slides were washed and counterstained with hem atoxylin. After staining, each section of tissue was visually inspected under light microscopy at 100x magnification, and each field was ranked on an overall scale from 0 to 3; with 0 indicating the ab sence of im munostaining; 1, weak staining; 2, moderate staining; and 3, str ong staining. A com posite score was then calculated based on a weighting of the num ber of fields that were strong, m oderate, weak or none. Staining scores are given in terms of (mean + standard deviation).
Tissues from prostate cancer patients were in spected by a pathologist and m arked for tumor regions and regions that were norm al adjacent to tum or (NAT), which was scored separately. Figure 7 shows CYP1B1 protein staining in cancer region, BPH, and NAT for AfricanAmericans and Caucasians. CYP1B1 protein was observed to be localized in the cytoplasm of prostate cancer cells with som e expression in sm ooth m uscle cells. W hile staining intensity varied considerably between individuals, overall the m ost intense staining was found in tum or areas (1.53 + 0.71), followed by BPH (1.45 + 0.5), and norm al adjacent (1.32 + 0.74). W hen comparing between races, there were high varia tion leading to large standard deviation but overall, highest expression of CYP1B1 was found in the tum or regions of African Am erican samples (1.57+ 0.87) and weakest in the norm al regions of Caucasian sam ples (1.2 + 0.73), From the pre-existing BPH and prostate cancer obtained from African-Am erican and Caucasian patients, and norm al healthy from African-American, DNA was collected by using a DNA extraction kit (Qiagen, Valencia, CA). Qu antity and quality of DNA was m easured at 260 nm and 280 nm by the use of a spectrophotom eter. A two-step polymerase chain reaction (PCR) procedure was designed for the analysis of CYP1 B1 polymorphisms. The primers of four of the polymorphic sites studied so far (codons 119, 432, 449, and 453) and PCR conditions are summarized in Table 1 . In the first PCR, DNA (10 ng) was am plified in a 20 ul reaction containing 1.5 m M MgCl 2 , 0.8 m M dNTP m ix, PCR buffer, and 0.5 units of Red-Taq polymerase (Sigm a-Aldrich, St. Louis, MO), al ong with prim er sets designed to contain the polymorphic sites (Table 2 ). In the sequence-specific PCR (SSP), each polym orphic fragm ent was further am plified under sim ilar conditions as the first-step PCR except for the use of SSP primer sets (Table 2) . Each of the SSP produc ts were electrophoretically separated on 3% agarose gels using 200 volts at am bient tem perature. The products were then visualized by ethidium bromide staining under UV light and recorded in the Alpha Im ager Gel Documentation System. To confirm genotyping, products of th e first PCR were subjected to direct DNA sequencing. In the case of the codon 449 polym orphism, direct sequencing was performed on all samples. DNA was purified from gels using a QIAquick PCR purification kit (Qiagen; Valencia, CA). Sequence analysis of purified products was then determined by using the first PCR prim ers and ABI 377 Sequencer and Dye Term inator Cycle sequencing kit (Applied Biosystem s Inc.; Foster City, CA). Confirm ation of DNA sequence was done on at least 3 representative sam ples for each of the polym orphic types. Frequencies of the various genotypes and allele types of CYP1B1 polymorphisms in the different categorie s of sam ples were determ ined and tabulated. Chi-square analysis was used to test each of the polym orphisms for differences in genotypic and allelic f requencies between W hites and Blacks as well as between BPH and prostate cancer. Relative risk associated with a particular ge notype or allele was estim ated by calculating odds ratios (OR) along with 95% conf idence intervals (CI). In African-Am erican sam ples, further analyses included case-control, linkage disequilibrium, and haplotype evaluation.
Results of the genotypic and allelic frequencie s of the three SNP sites of the CYP1B1 gene between African-Am ericans and Caucasians for BPH and prostate cancer, and total patients (including African-American controls) are shown in Tables 3 and 4 , respectively. Interestingly in total patients, the variant genotype at all 3 codons differ significantly between AfricanAmericans and Caucasians. The T/T genotype at codon 119 are highly predom inant in AfricanAmericans as com pared to Caucasians (C hi-square, P<0.001). OR (95% CI) were 2.71 (1.61-4.55) and 3.55 (1.96-6.43) for the G/ T and T/T genotypes, respectively, in Blacks com pared to Whites. At codon 432, the C/G and G/G genotypes were m uch greater in African-Am ericans with OR (95% CI) values of 3.90 (2.03-7.52) a nd 12.09 (5.95-24.58) as com pared to Caucasians (Chi-square, P<0.001). The polym orphism as codon 453 also proved to be different between Blacks and W hites although the variant A/G a nd G/G genotypes were m uch greater in Caucasians (Chi-square, P<0.001). Thus the OR ( 95% CI) values were lower for Blacks with values of 0.17 (0.09-0.34) for A/ G and 0.10 (0.01-1.02) for the G/G genotypes as com pared to Caucasians. Significant differences in genotype frequencies between Blacks and W hites also occurred when data were evaluated just among the prostate cancer patients at all 3 codons (Table  3) . When classified among the BPH patients, si gnificant differences were observed at the codon 432 and 449 sites but not the 119 site (Table 3) . This may be due to the sm all N size of BPH patients.
Likewise when evaluating allele frequenc ies between African-Am ericans and Caucasians, significant differences were observed at all 3 SNP sites in total patients (P<0.001; Table 4 ). This was also true in prostate cancer patients at all 3 sites (P<0.001; Table 4 ). In BPH patients, significance was only found at the codon 432 site a nd lack of significance for other two sites may be due to the small BPH patient N size.
A case-control study was perform ed on African -American as 97 healthy controls and 97 age-matched prostate cancer specimens were obtained. In addition to the 3 polymorphic sites, the codon 449 SNP site was also evaluated. Table 5 shows the results of genotypic and allele frequencies in prostate cancer and controls at these 4 polym orphic sites. The polym orphism at codon 453 was relatively low in frequency as the homozygous variant (G/G) was not observed in any patient. Frequencies in healthy controls were in Hardy-Weinberg equilibrium at these sites. When compared to healthy volunteers, no differe nces in polymorphic frequencies were observed in prostate cancer cases at codons 119, 432, a nd 449. However, the SNP at codon 453 proved to play a protective role as cancer cases had a si gnificantly lower frequency of the variant A/G genotype when compared to healthy controls (P=0.035). The OR was 0.16 with a 95% CI of 0.05 to 0.51 for the A/G genotype as com pared to A/A. In concordance, the allele frequency also differed with the variant G being much lower in prostate cancer cases (P=0.024).
Linkage disequilibrium analysis was perf ormed to determ ine any linkage between the 4 polymorphic sites. Healthy control sam ples were analyzed and interestingly, a strong linkage was observed between the codon 432 and codon 449 sites (Table 6 ). The D-value between these two sites were 0.1905. No linkages were observed between other polymorphic sites. Since these two sites were linked, haplotype analysis was performed between prostate cancer cases and controls. Interestingly as shown in Tabl e 7, the 432G -449C haplotype proved to be significantly associated for cancer as 6.3% of th is combination was found in cases com pared to just 1.0% in controls (P=0.016).
Clinical and pathological inform ation were obtained for a portion of the prostate cancer patients. Cancer sam ples were classified in te rms of stage and due to the sm all N size when divided between races, stage classifications were m ade as < T2c or > T2c. Results for each race is shown in Table 8 . No differences were obs erved between stages for either race although sample size is small. Likewise, cancer samples were classified in terms of pathological grade and were based as < 7 or > 7. Table 9 shows the results of sa mples based on grade for both Blacks and Whites and no differences were observed. 
KEY RESEARCH ACCOPLISHMENTS:
• Evaluated CYP1B1 RNA expression in prostate cell lines.
• Evaluated CYP1B1 RNA expression in BPH and prostate cancer samples.
• Evaluated CYP1B1 protein in BPH and prostate cancer samples.
• Evaluated CYP1B1 SNPs in healthy controls, BPH and prostate cancer samples.
• Evaluated linkages between SNP sites.
• Evaluated SNP haplotypes between cases and controls.
• Evaluated SNPs in stages and grade of prostate cancer samples.
REPORTABLE OUTCOMES:
Abstract presented at the American Association for Cancer Research (April, 2006) . The significances of the research performed to date are the following: 1) CYP1B1 RNA expression is higher in cancer ous com pared to norm al prostate cell lines from Caucasian. 2) CYP1B1 RNA expression is higher in pros tate cancer tissue com pared to BPH from Caucasian.
3) CYP1B1 protein is localized in the cytoplas m of prostate cancer cells with som e expression in smooth muscle cells. 4) CYP1B1 protein expression on average is hi gher in prostate tum or region com pared to normal adjacent region. 5) CYP1B1 codon 119 T variant genotype and allele are significantly higher in AfricanAmericans with prostate cancer compared to Caucasians. 6) CYP1B1 codon 432 G variant genotype and a llele frequency are significantly higher in African-Americans compared to Caucasians with BPH or prostate cancer. 7) CYP1B1 codon 453 G variant genotype and a llele frequency are significantly lower in African-Americans compared to Caucasians with prostate cancer. 8) In African-Americans, no associations found for prostate cancer at codons 119, 432, and 449 SNP sites. However, the G variant at codon 453 played a protective role against cancer. 9) In African-Am ericans, polym orphisms at codons 432 and 449 were in linkage disequilibrium. 10) In African-Americans, the 432G-449C haplotype is observed to be associated with prostate cancer. 11) CYP1B1 polymorphisms did not correlate with stage or grade of prostate cancer in AfricanAmericans and Caucasians.
CONCLUSIONS:
CYP1B1 expression is higher in prostate cancer compared to BPH tissue or normal cells. Racial differences in polym orphisms of the CYP1 B1 gene exist and therefore, m ay identify the population with higher risk for prostate cancer.
